X

Trial Profile

Open-label Extension Study of Long-term Safety and Efficacy of NNC6019-0001 in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 18 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Coramitug (Primary)
Indications Cardiomyopathies
Focus Therapeutic Use
Sponsors Novo Nordisk; Prothena

Most Recent Events

30 May 2024 Planned End Date changed from 29 Feb 2028 to 28 Aug 2028.
21 Feb 2024 Status changed from not yet recruiting to recruiting.
21 Feb 2024 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health;NCT06260709).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com